Asthma and cystic fibrosis: A tangled web

Pediatric Pulmonology

Volumn 49, Issue 3, 2014, Pages 205-213

  Kent, Brian D ^a   Lane, Stephen J ^a   Van Beek, Edwin J ^b   Dodd, Jonathan D ^c   Costello, Richard W ^d   Tiddens, Harm A W M ^e  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d BEAUMONT HOSPITAL   (Ireland)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

asthma; atopy; cystic fibrosis; inhaled corticosteroids

Indexed keywords

ASTHMA; ATOPY; CYSTIC FIBROSIS; INHALED CORTICOSTEROIDS;

ANTI-ASTHMATIC AGENTS; ASTHMA; CYSTIC FIBROSIS; HUMANS; LUNG; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84894248884     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22934     Document Type: Article

References (84)

1. Balfour-Lynn IM, Elborn JS,. " CF asthma": what is it and what do we do about it ? Thorax 2002; 57: 742-748.
2. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S,. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28: 231-241.
3. Koch C, McKenzie SG, Kaplowitz H, Hodson ME, Harms HK, Navarro J, Mastella G,. International practice patterns by age and severity of lung disease in cystic fibrosis: data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatr Pulmonol 1997; 24: 147-154; discussion 159-161.
4. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ,. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332: 133-138.
5. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD,. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354: 541-545.
6. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH,. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
7. Asthma GIf. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2010.
8. Pratter MR, Curley FJ, Dubois J, Irwin RS,. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med 1989; 149: 2277-2282.
9. Brand PL, van der Ent CK,. The practical application and interpretation of simple lung function tests in cystic fibrosis. J R Soc Med 1999; 92: 2-12.
10. Tiddens HA, Donaldson SH, Rosenfeld M, Pare PD,. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively ? Pediatr Pulmonol 2010; 45: 107-117.
11. Stanbrook MB, Corey M, Tullis DE,. The repeatability of forced expiratory volume measurements in adults with cystic fibrosis. Chest 2004; 125: 150-155.
12. Hordvik NL, Konig P, Morris D, Kreutz C, Barbero GJ,. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis 1985; 131: 889-893.
13. Brand PL,. Bronchodilators in cystic fibrosis. J R Soc Med 2000; 93: 37-39.
14. van Haren EH, Lammers JW, Festen J, van Herwaarden CL,. Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adult patients with cystic fibrosis. Eur Respir J 1992; 5: 1083-1088.
15. Rodwell LT, Anderson SD,. Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study. Pediatr Pulmonol 1996; 21: 282-289.
16. Eggleston PA, Rosenstein BJ, Stackhouse CM, Alexander MF,. Airway hyperreactivity in cystic fibrosis. Clinical correlates and possible effects on the course of the disease. Chest 1988; 94: 360-365.
17. Weinberger M,. Airways reactivity in patients with CF. Clin Rev Allergy Immunol 2002; 23: 77-85.
18. Valverde-Molina J, Sanchez-Solis M, Pastor-Vivero MD, Garcia-Marcos L,. [Association between chronic colonization or infection with Pseudomonas aeruginosa and bronchial hyperreactivity in patients with cystic fibrosis]. Arch Bronconeumol 2008; 44: 180-184.
19. Alothman GA, Ho B, Alsaadi MM, Ho SL, O'Drowsky L, Louca E, Coates AL,. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005; 127: 522-529.
20. Minasian C, Wallis C, Metcalfe C, Bush A,. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008; 43: 1078-1084.
21. Haverkamp HC, Dempsey JA, Miller JD, Romer LM, Pegelow DF, Lovering AT, Eldridge MW,. Repeat exercise normalizes the gas-exchange impairment induced by a previous exercise bout in asthmatic subjects. J Appl Physiol 2005; 99: 1843-1852.
22. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, Zamel N,. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010; 138: 682-692.
23. Caudri D, de Jongste JC,. Exhaled nitric oxide and childhood asthma. J Pediatr 2010; 156: 514; author reply 514-515.
24. Grasemann H, Kurtz F, Ratjen F,. Inhaled l -arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 208-212.
25. Brightling CE,. Clinical applications of induced sputum. Chest 2006; 129: 1344-1348.
26. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID,. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
27. Elizur A, Cannon CL, Ferkol TW,. Airway inflammation in cystic fibrosis. Chest 2008; 133: 489-495.
28. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ,. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001; 16: 1425-1431.
29. Eickmeier O, Huebner M, Herrmann E, Zissler U, Rosewich M, Baer PC, Buhl R, Schmitt-Grohe S, Zielen S, Schubert R,. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 2010; 50: 152-157.
30. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW,. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 822-828.
31. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, Ranganathan S,. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184: 75-81.
32. Fahy JV,. Remodeling of the airway epithelium in asthma. Am J Respir Crit Care Med 2001; 164: S46-S51.
33. Tiddens HA, Koopman LP, Lambert RK, Elliott WM, Hop WC, van der Mark TW, de Boer WJ, de Jongste JC,. Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. Eur Respir J 2000; 15: 735-742.
34. Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk TJ,. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011; 365: 119-126.
35. Stick SM, Brennan S, Murray C, Douglas T, von Ungern-Sternberg BS, Garratt LW, Gangell CL, De Klerk N, Linnane B, Ranganathan S, Robinson P, Robertson C, Sly PD,. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155: 623-628; e621.
36. Loeve M, van Hal PT, Robinson P, de Jong PA, Lequin MH, Hop WC, Williams TJ, Nossent GD, Tiddens HA,. The spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease. Thorax 2009; 64: 876-882.
37. McDermott S, Barry SC, Judge EE, Collins S, de Jong PA, Tiddens HA, McKone EF, Gallagher CC, Dodd JD,. Tracheomalacia in adults with cystic fibrosis: determination of prevalence and severity with dynamic cine CT. Radiology 2009; 252: 577-586.
38. de Jong PA, Muller NL, Pare PD, Coxson HO,. Computed tomographic imaging of the airways: relationship to structure and function. Eur Respir J 2005; 26: 140-152.
39. Lynch DA, Newell JD, Tschomper BA, Cink TM, Newman LS, Bethel R,. Uncomplicated asthma in adults: comparison of CT appearance of the lungs in asthmatic and healthy subjects. Radiology 1993; 188: 829-833.
40. Brown HM, Storey G, George WH,. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972; 1: 585-590.
41. Foundation CF,. Cystic Fibrosis Foundation Patient Registry Annual Report 2006. Cystic Fibrosis Foundation, Bethesda, MD; 2006.
42. Balfour-Lynn IM, Welch K,. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2009: CD001915.
43. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ,. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008; 153: 746-751.
44. De Boeck K, Vermeulen F, Wanyama S, Thomas M,. Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis. Eur Respir J 2011; 37: 1091-1095.
45. Ross KR, Chmiel JF, Konstan MW,. The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs 2009; 11: 101-113.
46. van Haren EH, Lammers JW, Festen J, Heijerman HG, Groot CA, van Herwaarden CL,. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995; 89: 209-214.
47. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, Elborn JS,. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173: 1356-1362.
48. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR,. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2: 686-688.
49. Cheng K, Ashby D, Smyth R,. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 2000; CD000407.
50. Barry SC, Gallagher CG,. Corticosteroids and skeletal muscle function in cystic fibrosis. J Appl Physiol 2003; 95: 1379-1384.
51. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV,. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126: 515-523.
52. Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RL,. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007; 132: 1212-1218.
53. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA,. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999; 28: 248-254.
54. Halfhide C, Evans HJ, Couriel J,. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2005; CD003428.
55. Dodd JD, Barry SC, Daly LE, Gallagher CG,. Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. J Cyst Fibros 2005; 4: 101-105.
56. Serisier DJ, Coates AD, Bowler SD,. Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest 2007; 131: 1181-1187.
57. Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA,. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991; 99: 1088-1092.
58. Konig P, Poehler J, Barbero GJ,. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol 1998; 25: 32-36.
59. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED,. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207.
60. Salvatore D, D'Andria M,. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatr Pulmonol 2002; 34: 11-15.
61. Hordvik NL, Sammut PH, Judy CG, Colombo JL,. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol 1999; 27: 43-53.
62. Hordvik NL, Sammut PH, Judy CG, Colombo JL,. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002; 34: 287-296.
63. Schmitt-Grohe S, Eickmeier O, Schubert R, Bez C, Zielen S,. Anti-inflammatory effects of montelukast in mild cystic fibrosis. Ann Allergy Asthma Immunol 2002; 89: 599-605.
64. Stelmach I, Korzeniewska A, Stelmach W, Majak P, Grzelewski T, Jerzynska J,. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Ann Allergy Asthma Immunol 2005; 95: 372-380.
65. Schmitt-Grohe S, Eickmeier O, Naujoks C, Schubert R, Lentze MJ, Zielen S, Rietschel E,. Effects of long-term treatment with montelukast in mild cystic fibrosis (long term treatment with montelukast in cystic fibrosis). Respir Med 2007; 101: 684.
66. Conway SP, Etherington C, Peckham DG, Whitehead A,. A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis. J Cyst Fibros 2003; 2: 25-228.
67. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ,. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412-1418.
68. Cosio BG, Soriano JB,. Theophylline again? Reasons for believing. Eur Respir J 2009; 34: 5-6.
69. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ,. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99: 8921-8926.
70. Pan SH, Canafax DM, Le CT, Cipolle RJ, Uden DL, Warwick WJ,. Bronchodilation from intravenous theophylline in patients with cystic fibrosis: results of a blinded placebo-controlled crossover clinical trial. Pediatr Pulmonol 1989; 6: 172-179.
71. Avital A, Sanchez I, Holbrow J, Kryger M, Chernick V,. Effect of theophylline on lung function tests, sleep quality, and nighttime SaO2 in children with cystic fibrosis. Am Rev Respir Dis 1991; 144: 1245-1249.
72. Louw C, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG,. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 2007; 74: 411-417.
73. Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P, Rost KD, Harnest U, Kroemer B, Albrecht A, Bredenbroker D,. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006; 61: 72-78.
74. Liu S, Veilleux A, Zhang L, Young A, Kwok E, Laliberte F, Chung C, Tota MR, Dube D, Friesen RW, Huang Z,. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther 2005; 314: 846-854.
75. Strunk RC, Bloomberg GR,. Omalizumab for asthma. N Engl J Med 2006; 354: 2689-2695.
76. van der Ent CK, Hoekstra H, Rijkers GT,. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62: 276-277.
77. Zirbes JM, Milla CE,. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43: 607-610.
78. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM,. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
79. Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozzi L, Wajdula J, Zang C, Nelson H, Raible D,. Efficacy/safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2010; 37: 1352-1359.
80. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT,. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174: 753-762.
81. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P,. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-558.
82. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M,. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
83. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M,. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-1431.
84. Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RMYN, Zhou S, Raible D, O'Byrne PM,. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183: 1007-1014.